Literature DB >> 26309093

The Potentiation of IFN-γ and Induction of Cytotoxic Proteins by Pegylated IL-10 in Human CD8 T Cells.

Ivan Ho Chan1, Victoria Wu1, Melissa Bilardello1, Elliot Mar1, Martin Oft1, Peter Van Vlasselaer1, John Brian Mumm1.   

Abstract

Interleukin-10 (IL-10) exerts both immunosuppressive and immunostimulatory effects. While the immunosuppressive effects are widely known, it has only been recently reported that pegylated recombinant human IL-10 (PEG-rHuIL-10) elicits potent interferon-γ (IFN-γ) and CD8 T-cell-dependent antitumor effects in murine tumor models. In this study, we show that PEG-rHuIL-10 exerts immune inhibitory effects on human peripheral blood mononuclear cell (PBMC) bulk cultures and stimulatory effects in CD8 T cells within the same culture. Also, in isolated CD8 T cells, PEG-rHuIL-10 potentiates prototypic Tc1 cytokine IFN-γ expression and induces perforin and granzyme B secretion. IFN-γ and granzyme B secretion is dependent on T-cell receptor ligation and is therefore not indiscriminately released by PEG-rHuIL-10 treatment. STAT3, NF-κB, AP1, and MEK inhibition blocks IFN-γ potentiation, while perforin induction is impeded by AP1 inhibition, and granzyme B induction is blocked by both AP1 and MEK inhibition. These results extend previous pegylated IL-10 preclinical findings to human CD8 T cells and implicate a strong degree of translation for pegylated IL-10 use in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26309093     DOI: 10.1089/jir.2014.0221

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  12 in total

1.  Oral IL-10 suppresses colon carcinogenesis via elimination of pathogenicCD4+ T-cells and induction of antitumor CD8+ T-cell activity.

Authors:  Tao Gu; Magdia De Jesus; Heather C Gallagher; Thomas P Burris; Nejat K Egilmez
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

Review 2.  Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.

Authors:  Romualdo Barroso-Sousa; Patrick A Ott
Journal:  Curr Oncol Rep       Date:  2018-11-15       Impact factor: 5.075

Review 3.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

4.  Cryo-EM structure of the IL-10 receptor complex provides a blueprint for ligand engineering.

Authors:  Robert A Saxton; K Christopher Garcia
Journal:  FEBS J       Date:  2021-09-20       Impact factor: 5.622

5.  Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

Authors:  Aung Naing; Kyriakos P Papadopoulos; Karen A Autio; Patrick A Ott; Manish R Patel; Deborah J Wong; Gerald S Falchook; Shubham Pant; Melinda Whiteside; Drew R Rasco; John B Mumm; Ivan H Chan; Johanna C Bendell; Todd M Bauer; Rivka R Colen; David S Hong; Peter Van Vlasselaer; Nizar M Tannir; Martin Oft; Jeffrey R Infante
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

6.  PEG-rIL-10 treatment decreases FoxP3(+) Tregs despite upregulation of intratumoral IDO.

Authors:  Ivan H Chan; Victoria Wu; Melissa Bilardello; Brett Jorgenson; Harminder Bal; Scott McCauley; Peter Van Vlasselaer; John B Mumm
Journal:  Oncoimmunology       Date:  2016-06-27       Impact factor: 8.110

7.  IL-10: Expanding the Immune Oncology Horizon.

Authors:  Ivan H Chan; Victoria Wu; Scott McCauley; Elizabeth A Grimm; John B Mumm
Journal:  Receptors Clin Investig       Date:  2015-11-04

8.  Mechanism of IFN-γ in regulating OPN/Th17 pathway during vascular collagen remodeling of hypertension induced by ANG II.

Authors:  Lei Jiang; Pengcheng He; Yong Liu; Jiyan Chen; Xuebiao Wei; Ning Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10.

Authors:  Robert A Saxton; Naotaka Tsutsumi; Leon L Su; Gita C Abhiraman; Kritika Mohan; Lukas T Henneberg; Nanda G Aduri; Cornelius Gati; K Christopher Garcia
Journal:  Science       Date:  2021-03-19       Impact factor: 63.714

10.  PEGylated IL-10 Activates Kupffer Cells to Control Hypercholesterolemia.

Authors:  Ivan H Chan; Dennis Van Hoof; Marina Abramova; Melissa Bilardello; Elliot Mar; Brett Jorgensen; Scott McCauley; Harminder Bal; Martin Oft; Peter Van Vlasselaer; John B Mumm
Journal:  PLoS One       Date:  2016-06-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.